Replies to post #4370 on Arena Pharmaceuticals, Inc. (ARNA)

[lovethatgreen]

that article is so freakin inaccurate its worse than pathetic...

the FDA in my mind didnt show up to adcom with any heart worry issues..

it was only in the minds of the panel members that DIDNT know sheet about what they were there for

there were no heart issues period after 20,000 electro cardiograms.

the big deal was the rat cancer issue that was finally buried..

qnexa is safer than lorqess my azz

kaul imo LOOKED LIKE A FOOL AT ADCOM

[The_Bull]

Dont forget even up to the DAY of ADCOM meeting, people and hedge funds were all favoring our competitors. Just be satisfied with your DD. Cause it could get rocky we still have over 5 weeks before the actual day. What I am hoping for is the FDA to approve Lorcaserine early.....that would catch everyone off guard and this would POP so big you could hear it around the world......LOL

[lovethatgreen]

Even if the drug is approved next month, analysts believe the company will be required to perform post-approval studies regarding cardiovascular risks.

analysts?..lol ...you mean bloggers parading around like they know WTF is going on as they did prior to adcom?

There were no cardio problems with 8000 tested and 20,000 electro cardiograms

Meanwhile, Vivus' Qnexa is expected to hit the U.S. market first. That and Qnexa's superior efficacy will make it "the obesity therapy of choice," wrote Leerink Swann analyst Steve Yoo in a research note published Friday.

wow this guy is on top of it isnt he not a Q..VVUS has no manufacturing set up for Qnexa... where by ARNA does.. Lorcaserin is in line for 1st approval dibs most likely... and as stated in the CC, they are ready to roll now superior efficacy..yeah baby!!!!...qnexa BSBSBS weigh the risks

Also working against lorcaserin are questions about whether an echocardiogram – a sonogram of the heart —should be required before the drug is prescribed. It's a costly test, and added to "the lower efficacy compared to Qnexa could limit lorcaserin's use," wrote Oppenheimer analyst Bret Holley in a research note published Friday.

Heres another clown..these ideas came from 3 maybe 4 panel members while the FDA mentioned nothing about any of this in their presentation in the AM of adcom

I thinks its highly questionable how much more they will have to do concerning the heart valve deal..but arena did say they were prepared to do whatever is required, during their am presentation prior to idiots rambling on about nothing...and it would all be post approval

Of course, obesity is a lucrative market for drug makers, and could offer plenty of room for multiple therapies. And even a runner-up drug can generate big sales. And Leerink's Yoo upgraded Arena to Outperform predicting that lorcaserin could hit the market by next March.


a runner up my azz...if the risks are laid out to the patient...lorquess verses qnexa especially to a woman, I would have to bet for that extra 1 to 2 percent weight loss, she'd be reaching for lorcaserin

lets see..should I risk clef pallet to a new born and possibly a heart attack with qnexa, or, should i put up with headache that disappears after a few days and ther e is no detox with lorqess? and march poopy cock..how bout sept it gets into the market

then theres the detox mandatory after 90 days cause of the phentermine... and topiramate is for epilepsy and does nothing for weight loss on its own...another complete joke of an issue blown out of the water...maybe I should become a freakin analyst.lollool

Contrave is out in Pluto territory and has no bearing on this for the next 1 to 2 years..


so the stock will remain volatile.

wow wow wow ...tell me something I dont know!!!!